Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Adipose tissue as a site of immune activation and dysfunction in individuals with obesity and asthma.

bioRxiv : the preprint server for biology·2026
Same author

Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.

Circulation. Heart failure·2026
Same author

Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.

Journal of the American Heart Association·2025
Same author

RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.

The Journal of endocrinology·2025
Same author

Regional and systemic adipose mass and peripheral conduit artery function.

Diabetes research and clinical practice·2025
Same author

Increased formation of angiotensin II from angiotensin I in individuals of African descent.

Journal of hypertension·2025

関連する実験動画

Updated: Jul 4, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

エプレレノン:心血管の保護

Nancy J Brown1

  • 1Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232-6602, USA. nancy.j.brown@vanderbilt.edu

Circulation
|May 21, 2003
PubMed
まとめ
この要約は機械生成です。

アルドステロンは臓器損傷を引き起こすが,非選択的阻害薬には副作用がある. 新しい選択性アルドステロン阻害剤であるエプレレノン (eplerenone) は,心血管疾患と腎臓疾患の治療において,安全性の向上を約束しています.

さらに関連する動画

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

関連する実験動画

Last Updated: Jul 4, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

科学分野:

  • 心血管医学は,心血管医学である.
  • ネフロロジーはネフロロジーを用います.
  • エンドクリノロジー エンドクリノロジー

背景:

  • アルドステロンは,ミネラルコルチコイド受容体を通して心血管および腎臓の損傷に寄与する.
  • スピロノラクトンなどの非選択性アルドステロン受容体対抗剤は,副作用のために制限があります.

研究 の 目的:

  • 選択性アルドステロン受容体対抗体であるエプレレノン (eplerenone) の薬理学,有効性,安全性をレビューする.
  • 心血管の毒性におけるアルドステロンの役割と選択的対抗性の利点について議論します.

主な方法:

  • 動物実験および臨床試験から得られた既存のデータのレビュー.
  • エプレレノンの薬理学的評価 エプレレノンの薬理学的評価
  • 効果と安全性プロファイルの分析.

主要な成果:

  • エプレレノンは,選択的なアルドステロン受容体アンタゴニストです.
  • 選択的対抗性は,非選択的エージェントに比べて潜在的な利点を提供します.
  • 新興の証拠は,心血管の毒性におけるアルドステロンの役割を強調しています.

結論:

  • エプレレノンは,アルドステロン過剰に関連した状態を管理するための潜在的に安全で効果的な選択肢を提供します.
  • 選択的アルドステロン受容体対抗は,心血管および腎臓の保護のための有望な治療戦略です.